Sun Pharma, Intrexon partner on synthetic eye drugs
This article was originally published in Scrip
Executive Summary
Sun Pharmaceutical Industries and Germantown, Maryland-based Intrexon will develop controllable gene-based therapies for eye diseases in a joint venture that combines Sun Pharma's specialty product development and manufacturing expertise – and the Mumbai, India company's global reach – with Intrexon's synthetic biology technology.
You may also be interested in...
Finance Watch: Intrexon Reorganizes, Raises Cash And Becomes Precigen
The new year starts with a strategic shift by Intrexon. Also, Roivant and Sumitomo Dainippon launch Sumitovant, Melinta reorganizes through Chapter 11 bankruptcy, Acorda arranges debt relief and CF PharmTech raises a $90m series E round.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.